{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:18:12Z","timestamp":1786997892695,"version":"build-2736575974"},"reference-count":33,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:00:00Z","timestamp":1681689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.urolonc.2023.04.003","type":"journal-article","created":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T23:35:59Z","timestamp":1682984159000},"page":"261-273","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["The efficacy and safety outcomes of lower dose BCG compared to intravesical chemotherapy in non\u2013muscle-invasive bladder cancer: A network meta-analysis"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8369-9712","authenticated-orcid":false,"given":"Tatsushi","family":"Kawada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Yanagisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Bekku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Laukhtina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"von Deimling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Chlosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Pradere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy Yuen-Chun","family":"Teoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Babjuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoo","family":"Araki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2023.04.003_bib0001","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2023.04.003_bib0002","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and Carcinoma in Situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2023.04.003_bib0003","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2023.04.003_bib0004","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1464-410X.2002.02722.x","article-title":"Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Gu\u00e9rin with a reduced dose of 27 mg in superficial bladder cancer","volume":"89","author":"Mart\u00ednez-Pi\u00f1eiro","year":"2002","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2023.04.003_bib0005","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/01.ju.0000173919.28835.aa","article-title":"Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial","volume":"174","author":"Martinez-Pineiro","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2023.04.003_bib0006","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2023.04.003_bib0007","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.urolonc.2023.04.003_bib0008","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.urolonc.2023.04.003_bib0009","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/jrsm.1054","article-title":"Automating network meta-analysis","volume":"3","author":"van Valkenhoef","year":"2012","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.urolonc.2023.04.003_bib0010","series-title":"NICE decision support unit technical support documents. NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials","author":"Dias","year":"2014"},{"key":"10.1016\/j.urolonc.2023.04.003_bib0011","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.urology.2007.07.017","article-title":"The safety and efficacy of different doses of bacillus Calmette Guerin in superficial bladder transitional cell carcinoma","volume":"70","author":"Agrawal","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2023.04.003_bib0012","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.eururo.2007.04.062","volume":"52","author":"Ojea","year":"2007","journal-title":"Eur. Urol."},{"key":"10.1016\/j.urolonc.2023.04.003_bib0013","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.aju.2015.07.002","article-title":"A comparative study between full-dose and half-dose intravesical immune bacille Calmette-Gu\u00e9rin injection in the management of superficial bladder cancer","volume":"13","author":"Kandeel","year":"2015","journal-title":"Arab J Urol"},{"key":"10.1016\/j.urolonc.2023.04.003_bib0014","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.urolonc.2020.01.002","article-title":"A prospective comparative study to assess the efficacy and tolerability of 2 different doses of intravesical bacillus Calmette-Guerin (BCG) in patients with non-muscle-invasive bladder cancer","volume":"38","author":"Sood","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2023.04.003_bib0015","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000471653","article-title":"Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Gu\u00e9rin) in superficial bladder cancer","volume":"20","author":"Rintala","year":"1991","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2023.04.003_bib0016","first-page":"119","article-title":"Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study","volume":"1","author":"Lamm","year":"1995","journal-title":"Urol Oncol Semin Orig Invest"},{"key":"10.1016\/j.urolonc.2023.04.003_bib0017","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S0022-5347(01)65673-8","article-title":"A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin","volume":"156","author":"Krege","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2023.04.003_bib0018","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0022-5347(01)65853-1","article-title":"A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma","volume":"156","author":"Lundholm","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2023.04.003_bib0019","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(01)61607-0","article-title":"5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma","volume":"161","author":"Malmstrom","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2023.04.003_bib0020","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/01.ju.0000080568.91703.18","article-title":"Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study","volume":"170","author":"Di Stasi","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2023.04.003_bib0021","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1464-410X.2006.06706.x","article-title":"Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Gu\u00e9rin in patients with high-risk bladder cancer","volume":"99","author":"G\u00e5rdmark","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2023.04.003_bib0022","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3109\/00365599.2012.694906","volume":"46","author":"Jarvinen","year":"2012","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.urolonc.2023.04.003_bib0023","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000273461","article-title":"Bacillus Calmette-Guerin versus gemcitabine for intravesical therapy in high-risk superficial bladder cancer: a randomised prospective study","volume":"84","author":"Porena","year":"2010","journal-title":"Urol Int"},{"key":"10.1016\/j.urolonc.2023.04.003_bib0024","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/cncr.24914","article-title":"Gemcitabine versus bacille Calmette-Gu\u00e9rin after initial bacille Calmette-Gu\u00e9rin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial","volume":"116","author":"Di Lorenzo","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2023.04.003_bib0025","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1200\/JCO.2008.20.8199","article-title":"Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance","volume":"28","author":"Addeo","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2023.04.003_bib0026","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.juro.2013.03.097","article-title":"The impact of intravesical gemcitabine and 1\/3 dose Bacillus Calmette-Gu\u00e9rin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial","volume":"190","author":"Gontero","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2023.04.003_bib0027","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/BF02550957","article-title":"BCG versus epirubicin in the prophylaxis of multiple superficial bladder tumours: results of a prospective randomized study using modified treatment schemes","volume":"28","author":"Melekos","year":"1996","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.urolonc.2023.04.003_bib0028","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/01.ju.0000150425.09317.67","article-title":"Bacillus Calmette-Guerin versus epirubicin for primary. secondary or concurrent carcinoma in situ of the bladder: results of a european organization for the research and treatment of Cancer-Genito-urinary Group phase III trial (30906)","volume":"173","author":"De Reijke","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2023.04.003_bib0029","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1442-2042.2005.01064.x","article-title":"Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer","volume":"12","author":"Cheng","year":"2005","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2023.04.003_bib0030","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1464-410X.2010.09891.x","article-title":"Maintenance therapy with bacillus Calmette-Guerin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer","volume":"108","author":"Hinotsu","year":"2011","journal-title":"Bju International"},{"key":"10.1016\/j.urolonc.2023.04.003_bib0031","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"Sylvester","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2023.04.003_bib0032","doi-asserted-by":"crossref","first-page":"140","DOI":"10.4111\/icu.20210340","article-title":"Low-dose versus standard-dose bacille Calmette\u2013Gu\u00e9rin for non-muscle-invasive bladder cancer: Systematic review and meta-analysis of randomized controlled trials","volume":"63","author":"Choi","year":"2022","journal-title":"Investig Clin Urol"},{"key":"10.1016\/j.urolonc.2023.04.003_bib0033","article-title":"Intravesical gemcitabine for non-muscle invasive bladder cancer","volume":"6","author":"Han","year":"2021","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143923001187?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143923001187?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:26:03Z","timestamp":1761042363000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143923001187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1078143923001187"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2023.04.003","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy and safety outcomes of lower dose BCG compared to intravesical chemotherapy in non\u2013muscle-invasive bladder cancer: A network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2023.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}